

Mastering PIK3CA Targeted Therapy in HR+/HER2- Breast Cancer

Pharmacists Leading the Way

Thursday, April 23, 2026
from 4:45 – 6:15pm

TCU Place in Salon A&B
Saskatoon, SK

*Mocktails and appetizers
will be served*

Precision oncology is changing how advanced HR+/HER2- breast cancer is managed — and oncology pharmacists are central to safe, effective delivery.

Experts will break down the clinical relevance of PIK3CA mutations, where targeted therapies fit in the treatment pathway, and what this means for your daily practice. Gain practical, pharmacist-focused strategies for patient counselling, monitoring, and preventing and managing treatment-related adverse events.

*Come for a mocktail.
Leave with concise,
practice-ready tips you
can use with patients
the very next day*

PANELISTS



MODERATOR

CHRISTINE PERAGINE

PhD, PharmD, BScPhm, RPh

Pharmacist Lead,
Oral Anticancer Medication Program
Sunnybrook Odette Cancer Centre
Toronto, ON



SANDEEP SEHDEV

MD, FRCPC

Medical Oncologist,
Lead of Breast Disease Site Group, Assistant Professor
The Ottawa Hospital Cancer Centre and U of Ottawa
Ottawa, ON



RABIA SHAHID

MD, MSc, FRCP(C)

Associate Professor, Department of Medicine
UGME Y3 and Y4 IM Rotation Director,
University of Saskatchewan
Saskatoon, SK

LEARNING OBJECTIVES

Describe the role of PIK3CA mutations in the prognosis of breast cancer patients and the clinical impact of PIK3CA pathway-targeted therapies

Develop comprehensive strategies for patient education and counselling regarding PIK3CA targeted therapies and their place in the patient treatment journey

Summarize the approach to monitoring and managing common adverse events associated with PIK3CA-targeted therapies

REGISTER NOW!

Delegates must be registered to the conference to participate

